Przerwy w podawaniu leków przeciwpadaczkowych podczas przejścia z oddziału intensywnej opieki do zwykłego oddziału: Analiza porównawcza u tych samych pacjentów
Antiseizure Medication Administration Gaps Across the ICU-to-Floor Transfer: A Matched Within-Patient Comparison
W skrócie
[Preprint - wstępne wyniki] Badanie wykazało, że leki przeciwpadaczkowe nie są podawane na czas u około 1 na 10 pacjentów podczas przejścia z oddziału intensywnej opieki do zwykłego oddziału szpitala. Przerwy w leczeniu podczas tego przejścia są 5-6 razy częstsze niż podczas normalnych dni hospitalizacji tego samego pacjenta. Wyniki sugerują potrzebę wprowadzenia specjalnej procedury kontroli ciągłości podawania leków w momencie przejścia pacjenta między oddziałami.
Oryginalny abstract (angielski)
Objective: Whether a scheduled antiseizure medication (ASM) continues on schedule across the ICU-to-floor transfer has not been characterized. We quantified ASM administration-gap frequency across this transfer and compared it with gap frequency during matched non-transfer intervals in the same patient and drug. Methods: In this retrospective MIMIC-IV (version 3.1) cohort study, we identified epilepsy and status-epilepticus admissions with an ICU stay followed by floor transfer and a scheduled ASM order active at ICU departure. A gap was defined as an interval exceeding 1.5 times the expected dosing interval between the last ICU dose and first floor dose, or no further dose before discharge, and compared with a matched non-transfer control interval in the same patient and drug (paired McNemar test). A multivariable model evaluated six prespecified clinical predictors; sociodemographic variables were summarized descriptively. Results: Among 2,469 ASM transition-by-drug observations (1,583 admissions, 1,335 patients), an administration gap occurred in 251 (10.2%; 95% CI, 8.7%-11.7%). Gap frequency across the transfer exceeded frequency during matched non-transfer control intervals in the same patient and drug: a paired rate difference of 5.8 percentage points (95% CI, 4.4-7.1; 7.5% vs 1.7%; P = 7.3 x 10^-22) before the transfer and 6.4 percentage points (95% CI, 4.9-7.9; 8.9% vs 2.5%; P = 1.9 x 10^-23) after. Gap rates were similar for intravenous-available (9.9%) and oral-only (11.4%) drugs (rate difference, 1.5 percentage points; 95% CI, -1.6 to 4.5; P = .34). None of six prespecified predictors reached significance after correction. Significance: An antiseizure medication administration gap occurred in approximately 1 of every 10 drug-transition observations at the ICU-to-floor transfer, exceeding matched non-transfer gap rates by 5.8 to 6.4 percentage points. This transfer-associated excess, rather than any single medication or patient characteristic, supports a structured medication-continuity check.